Trends in Longevity Care

Humans will live longer with AI and technology — not just longer, but healthier. How long do you plan to live? History shows every leap in science adds years to life: ✅ Clean water and sanitation added 20+ years to life expectancy in the 20th century. ✅ Vaccines and antibiotics extended it by another 10+ years. Now we’re entering a new era where AI and advanced technology become the next great longevity engine. 🔹 AI diagnostics: Studies show AI can detect cancers and heart disease with 95%+ accuracy, often years before symptoms appear. Early detection alone can increase survival rates by 30–50%. 🔹 Personalized medicine: Genomic AI is making tailored treatments possible, projected to cut adverse drug reactions by up to 70%. 🔹 Wearables & robotics: By 2030, over 1 billion people will use health-monitoring devices, empowering real-time interventions and healthier aging. 🔹 Drug discovery with AI: What once took 10–15 years can now be done in under 2 years, accelerating breakthroughs in anti-aging and regenerative medicine. 📊 The economic impact is massive: According to the World Economic Forum, increasing healthy life expectancy by just 1 year would add $38 trillion to the global economy. By 2030, the longevity economy (products & services for people over 50) is projected to reach $27 trillion. A healthier, longer-living population means extended productivity, delayed retirement, and reduced healthcare costs. Today, the global average life expectancy is 73 years. With AI and technology, experts forecast we could see healthy lifespans extend to 90–100 years within this century. This is more than just “adding years to life” — it’s about adding life to years. Imagine a world where people in their 80s and 90s remain as vibrant, curious, and productive as those decades younger. The convergence of AI and technology won’t just change how long we live. It will change what it means to live. #AI #Longevity #FutureOfHealth #TechnologyForGood #Innovation #LongevityEconomy

𝗧𝗵𝗲𝗿𝗲’𝘀 𝗮 $𝟮.𝟳𝗧 𝗹𝗼𝗻𝗴𝗲𝘃𝗶𝘁𝘆 𝗺𝗮𝗿𝗸𝗲𝘁 𝗵𝗶𝗱𝗶𝗻𝗴 𝗶𝗻 𝗽𝗹𝗮𝗶𝗻 𝘀𝗶𝗴𝗵𝘁. Most health and wellness companies are targeting the same high-performing, overextended 35-year-old. And honestly, fair enough: → They're chasing VO2 max tests → Buying supplements → Trying to stay ahead of illness → and tracking everything But at the same time, they’re juggling: → Non-stop pressure → Careers → Kids → Calendars They barely have time to engage with half the products we’re building. The thing is, there’s another group we rarely talk about, the "silver age." People between 55 and 75 who often have: → More time → More resources → and more immediate motivation to invest in their health And yet, most of the industry still overlooks them. → The global elderly care market hit $1.94T last year. Projected to reach $3.29T by 2032. → Seniors' health and wellness is set to double from $1.4T to $2.71T by 2033. Just look at the pain point: 📉 80% of adults 65+ have at least one chronic condition. 💊 40% of older adults take five or more prescription medications daily. 💔 25% are socially isolated, a risk comparable to smoking 15 cigarettes a day. 🦴 1 in 4 Americans over 65 falls each year, the leading cause of injury-related death. 🧠 6.7M people live with Alzheimer’s in the US alone, projected to nearly double by 2050. The interventions exist. They just haven’t been built or branded with this group in mind. → Personalized nutrition → Mobility and balance → Creatine, HRT, better sleep → Strength training for muscle loss prevention Most companies currently building for 55+ are focused only on minimizing symptoms but miss the value in engaging older demographics in preventative behavior to maximize the joy of their later years. One of the most thoughtful positive examples lately came from ŌURA. In their latest campaign, they didn’t lean on the usual fitness influencers. They featured older adults, with visible age, confident presence, and genuine vitality. It wasn’t performative or patronizing. Just a message that aging deserves to be seen too. We're talking about a multi-trillion dollar space, and most of the interventions already exist. But everything, the language, the branding, the way we design, still feels more targeted to the 30-something mindset. If you're building in the preventative health space, stop only thinking about early-life optimization and start considering later-life vitality! Would love to hear of any companies you feel do this particularly well?

Clinical Longevity Medicine: From Energy Decline to Tissue Repair Post 6 — The Hidden Pattern Behind Longevity Treatments At first glance, longevity medicine looks fragmented. Exercise. Fasting. Sleep optimization. Creatine. NMN. NAD strategies. CoQ10. Mitochondrial support. HBOT. IHHT. Cold exposure. Sauna. Red light therapy. Plasma dilution. Senolytic concepts. Regenerative medicine. Cellular therapies. It can look like a long list of unrelated treatments. Some target metabolism. Some target mitochondria. Some target inflammation. Some target recovery. Some target oxygen. Some target repair. Some target tissue regeneration. But when you look deeper, a pattern appears. Many of the most important longevity interventions are not random. They converge on one central biological goal: restoring the body’s capacity to produce, use, and allocate energy. Exercise improves mitochondrial biogenesis, VO₂max, insulin sensitivity, muscle quality, and metabolic flexibility. Fasting activates energy-sensing pathways and improves metabolic switching. Sleep restores mitochondrial function, hormonal balance, immune regulation, and repair capacity. Creatine supports cellular energy buffering, especially in muscle and brain. CoQ10 supports mitochondrial electron transport and ATP production. NMN and NAD strategies aim to support redox balance, sirtuin activity, and energy metabolism. IHHT and HBOT work through oxygen biology, mitochondrial signaling, vascular adaptation, and repair pathways. Cold and heat therapies challenge the system and stimulate adaptive energy responses. Red light therapy is being explored for mitochondrial signaling and cellular energy support. Even advanced approaches — plasma dilution, senolytic concepts, regenerative medicine, and cellular therapies — can be understood through the same lens: They aim to reduce biological burden, restore repair capacity, or improve the tissue environment so energy can be used more effectively. This is why I believe cellular energy is not just another topic in longevity medicine. It may be the organizing principle. Aging is not only the accumulation of damage. It is also the gradual loss of the energy required to repair that damage. And many of the interventions we already consider “longevity treatments” may work, at least in part, because they improve energy production, energy efficiency, energy allocation, or energy-dependent repair. The future of longevity medicine will not be a random menu of protocols. It will be a clinical strategy: Measure energy capacity. Identify tissue damage burden. Find the biological bottleneck. Choose the intervention that restores repair capacity. Because the real goal is not to collect more treatments. The real goal is to restore the energy required to maintain life, function, and resilience.

🚀 I just got back from A4M—the biggest anti-aging conference in the U.S.—here are my top 10 takeaways: 1. “Fringe” therapies are going mainstream. Ever heard of Therapeutic Plasma Exchange? It sounds wild—they drain your blood and replace plasma to clear out heavy metals, mold, and infections. But here’s the kicker: early data shows it can improve 30+ longevity biomarkers. It’s no crazier than cold plunges or red light therapy once sounded. Once these treatments get cheaper, they’ll be everywhere. Dr. Darshan Shah and Dobri Kiprov are leading the way. 2. Peptides are unstoppable. Despite regulatory headwinds, the demand for peptides hasn’t slowed. Custom formulations are thriving, doctors are obsessed, and GLP-1 drugs (like Ozempic) have only fanned the flames. This train isn’t stopping. 3. Women’s health is finally getting its moment and making up for lost time. From pregnancy to postpartum to menopause, care for women is getting nuanced and comprehensive. Doctors are focusing on the emotional and medical needs of every phase. This isn’t just healthcare—it’s care. Erika Schwartz, MD mastered this. 4. The rise of compounding pharmacies. Patients want customized treatments—tailored formulations, better delivery methods, and lower costs. Compounding pharmacies are taking big risks to meet that demand, and it’s pushing the entire industry forward. 5. Peter Attia dropped the mic (again). No one understands longevity like Peter Attia. His best line? “You cannot overestimate the importance of exercise. Contracting a muscle literally lowers blood sugar by bringing glucose receptors to the surface.” Simple. Actionable. Science-backed. 6. Love, Awe, and Mindset might be the real magic. We’re obsessed with the newest treatments, but the best doctors know this: ✨ Love ✨ Awe ✨ Mindset These emotions lower stress hormones, make us feel safe, and are huge predictors of longevity. Don't skip the human side of health. 7. AI + quantum computing will make doctors superhuman. In the next few years, healthcare information will increase by 3x.  Forward-looking doctors aren’t afraid of AI—they see it as a tool. Doctors aren’t being replaced—they’re becoming healers powered by machines that will unlock the kind of insights we can’t yet imagine. 8. Longevity is personal. There won’t be one magic protocol. The winners will create frameworks that let doctors deliver N=1 care—custom treatments for every individual. Longevity is a journey, not a prescription. 9. Longevity leaders are stepping up. Physicians and founders like David Luu, MD are building global, research-based communities like Longevity Docs to push boundaries and innovate. The people driving this movement are bold, brilliant, and collaborative. 10. Diagnostics are changing the game. Precision testing is the bedrock of modern longevity care. Doctors are demanding more specific insights to fine-tune treatment plans. TruDiagnostic and Ryan Smith are leading the charge here.

Longevity in 2026: The End of Biohacking. The Beginning of Biology. For years, longevity has been driven by fragmented interventions—supplements, peptides, protocols layered without sequence. 2026 marks a shift. Not toward more interventions… but toward integration, measurement, and biological coherence. ⸻ 1. AI is becoming clinical infrastructure Recent publications across Nature Publishing Group and npj Aging highlight: • Continuous digital phenotyping • Integration of wearables, labs, imaging • Early “digital twin” models for prediction This is no longer optimization. It is real-time biology tracking. ⸻ 2. Biological age is evolving We’ve moved beyond single-number outputs. The focus now is on: • DNA methylation and epigenetic clocks • Organ-specific aging signals • Inflammatory distortion of aging metrics The key insight: Aging is not one clock—it is a network losing synchronization . 3. The microbiome expands—now oral health Emerging 2026 data links the oral microbiome to: • Cardiovascular disease • Neuroinflammation • Cognitive decline Dentistry is no longer isolated. It is part of longevity medicine. ⸻ 4. Metabolic therapy is being reframed GLP-1–based therapies are evolving beyond weight loss: • Metabolic regulation • Inflammatory signaling • Restoration of metabolic flexibility But without restoring underlying capacity, pharmacology becomes compensation—not correction. ⸻ 5. Lifestyle is being revalidated—through mechanism Publications in The Lancet Healthy Longevity reinforce: • Exercise → mitochondrial signaling • Sleep → hormonal and immune timing • Meditation → inflammatory modulation This is not “wellness.” It is biological regulation. ⸻ 6. Genetics: important, but not destiny New 2026 data suggests ~50% heritability of lifespan. But the real takeaway: Genetics loads the system. Environment determines its trajectory. ⸻ Where this leaves us Longevity medicine is not about adding more. It is about: • Restoring rhythm • Rebuilding capacity • Measuring function, not just labs The future is not anti-aging. It is systems restoration. ⸻ If we continue treating pathways in isolation, we will continue to miss outcomes. Because longevity is not a pathway problem.

Family offices are pouring billions into longevity. Not as a trend. As a strategic imperative. Let me show you why. Ultra-high-net-worth individuals are realizing: What's the point of building wealth if you can't enjoy it in health? They're spending years accumulating capital. Then spending their final years managing decline. That's changing. The new playbook: 1. Build wealth (decades) 2. Extend healthspan (decades) 3. Enjoy both (decades) How family offices are investing in longevity: Personal Investments: Tier 1: Diagnostic assessment ($10K-$50K annually) - Comprehensive DNAmAge testing - 100+ biomarker panels - Advanced imaging - Performance testing - Microbiome and genetic analysis Tier 2: medical team ($50K-$200K annually) - Personal longevity physician - Concierge access to specialists Tier 3: Interventions ($50K-$500K+ annually) - Personalized protocols - Advanced treatments (peptides, senolytics, hyperbaric oxygen) - Longevity retreat experiences But that's just the beginning. Portfolio Investments (Longevity as asset class). Family offices are allocating capital to: 1. Longevity Biotech The thesis: aging is a treatable condition. The companies that crack it will be worth trillions. Notable investments: - Altos Labs ($3B from Bezos, Milner, others) - Calico (Alphabet/Google longevity bet) - Retro Biosciences ($180M to add 10 years to healthspan) 2. Longevity services & consumer brands The thesis: high-net-worth consumers will pay premium prices for credible longevity optimization. Examples: - Function Health (comprehensive biomarker testing) - Oura (sleep and recovery tracking) 3. Real Estate (longevity-focused hospitality) The thesis: longevity tourism will become the highest-margin segment of luxury hospitality. Where capital is going: - Acquiring or developing longevity resort properties - Partnering with medical teams to add credibility - Converting traditional wellness properties to medical-grade facilities Family office investments today become accessible interventions tomorrow. Example: - Complete genome testing: Millions of $$ (1990) -> Hundreds of $$ (2025) The same will happen with: - Biological age testing (getting cheaper) - Longevity diagnostics (scaling) - Advanced interventions (coming to mass market) My predictions: By 2030: - Longevity concierge medicine will be the fastest-growing segment of private medicine - Biological age optimization will be standard - Insurance will start covering preventive longevity care By 2035: - "Longevity advisor" will be as common as "financial advisor" - Longevity tourism will separate ultra-luxury from commodity hospitality Family offices see longevity as: - A personal imperative (extend their own healthspan) - An investment opportunity (massive TAM, early-stage market) - A network advantage (shared access to cutting-edge interventions) They're not waiting for longevity to go mainstream. They're funding it into existence. Let's discuss longevity advisory. DM me.

My fireside chat on #Longevity with Benjamin Cavalli from UBS in Zurich, part of the “Thriving in the Age of Disruption” gathering at the stunning 18th-century Zunfthaus zur Meisen. A great setting with 60 global entrepreneurs, investors, and visionaries. I shared our perspective at LifeX Ventures on what will help us live longer (delay death) and better (improve quality of life in later years), with a few examples: The near-term big innovations we’re investing in at LifeX: * Precision robotic surgery (e.g. Hypervision Surgical — the best surgeon may soon be an NVIDIA GPU, and there will be thousands of them) * Affordable world-class surgical care (e.g. World Class Health), * 24/7 AI doctors * Tackling obesity (which affects 40% of U.S. adults if defined by a BMI over 30 and shortens life by ~4 years; e.g. Ilant Health) * Proactive AI-powered early detection and monitoring before symptoms appear (e.g. Function Health) * Understanding why some people survive deadly cancers like pancreatic cancer (e.g. Cure51) * AI-driven recovery (e.g. Exer AI) * AI Robotics to make the latest cell and gene therapies (today one dose for one patient is over $300K) 10x cheaper to manufacture (e.g. Limula) * Personalized cancer treatment (e.g. Onc.AI, which brings clarity to cancer treatment decision-making using AI on top of diagnostic imaging, EMRs, blood tests, and genomics). Looking 10+ years ahead, we’re excited about more radical advances in longevity, a few examples: * Cellular and epigenetic reprogramming to restore cells so they function as when you are young (e.g. NewLimit and Retro Biosciences) * Senescent cell targeting to treat chronic conditions (e.g. Rubedo Life Sciences) * Xenotransplantation to grow compatible organs in pigs or chimpanzees and cryopreserve them so you can always transplant failing organs rather than “fix” them (e.g. eGenesis, Inc.) * Tissue regeneration inside the body (e.g. LyGenesis) and * 3D-printed tissues and organs for transplant. #AI #longevity

We’re at an inflection point in longevity science: for the first time, translational programs are mapping mechanistic targets to interventions that could expand healthspan—not just lifespan. Longevity is moving from hype to biology. Instead of chasing “anti-aging retreats,” credible programs are targeting the hallmarks of aging—genomic instability, epigenetic drift, mitochondrial decline, senescence, and chronic inflammation. What’s promising right now? mTOR modulation (rapalogs): Extends animal healthspan; human trials are underway. https://lnkd.in/ekwN9-WV Senolytics: Drugs that clear senescent cells reduce “inflammaging” in models; early human data are emerging. https://lnkd.in/e7529C4b NAD+/sirtuins: Boosting mitochondrial resilience — safe, but efficacy still under study. Partial epigenetic reprogramming: Resetting cellular age, moving from proof-of-concept toward translation. https://lnkd.in/eTF7FbfV The ecosystem: Big players (Altos Labs, Calico), biotechs (BioAge, Juvenescence), and a wave of consumer supplements. Funding is massive, but hype is high. The challenge: Will we create accessible, evidence-based longevity therapeutics — or a two-tier system of luxury “longevity clinics”? The next 3–5 years will decide. I'd love to hear your thoughts. 📚 Key refs: López-Otín Hallmarks of Aging; reviews on rapamycin, senolytics, and reprogramming. https://lnkd.in/ejesBrfQ

We meet atleast 20 companies every month building solutions for longevity. Billions of dollars are being spent. Met Bryan Jhonson who spends $2million every year on his own longevity. Sharing some observations from an investor and an health enthusiast perspective for India. #1 Everyone loves the idea of a pill or device that adds 50 years to life. But longevity is 80% lifestyle and 20% intervention. Companies chasing the 20% often overpromise and underdeliver. Don’t exploit people’s fear of death or disease to sell products & supplements leading to skepticism and distrust. #2 Blood tests and wearables measure everything now—glucose, cortisol, telomeres. But data without actionable insights is just noise. A longer life needs meaningful action, not just analytics. Don’t over emphasise on biomarkers without a feedback loop to fix it. Build tools that have clear clinical and user adoption pathways. #3 Investors want quick ROI, but longevity isn’t a sprint, it’s a marathon. Companies chasing valuations as a metric often neglect the slow, foundational research required. Your core product will accelerate your valuation if you deliver outcome. Don’t promise timelines that ignore the inherent long cycles of research, trials, and regulatory approvals. #4 The key isn’t to stop aging but to improve healthspan—living well until the end. Companies prioritizing quality over quantity of life are the real winners. Build systems on aging as a process to address muscle loss or inflammation rather than waiting for chronic disease onset. #5 You can’t engineer longevity if people won’t adopt the solutions. Companies that understand habit formation and human psychology will create an IP. The future of longevity isn’t in more tech but in accessible, scalable solutions—better sleep, balanced nutrition, and community support. These “boring” fixes will outlast flashy innovations. #6 Women experience aging differently but are often overlooked in longevity-focused research. Focus on women’s health. Also longevity studies need to be diverse. We can’t be using datasets primarily from high-income countries and build solutions for people in low and middle-income populations. #7 Don’t associate longevity with celebrity faces to generate PR. This will lack substance and meaningful validation. Remember, people don’t just want to live longer. They want to live better. Focus on delivering that as your metric. If you’re building something meaningful in this space, happy to exchange notes.